The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | 3-year follow-up of obinutuzumab, ibrutinib and venetoclax for CLL
Kerry Rogers, MD, The Ohio State University, Columbus, OH, outlines the results of a three-year follow up of the Phase II trial (NCT02427451) of obinutuzumab in combination with ibrutinib and venetoclax in patients with relapsed/refractory or previously untreated chronic lymphocytic leukemia (CLL). The follow-up study found that fixed duration of obinutuzumab plus ibrutinib plus venetoclax resulted in high overall response rates and undetectable minimal residual disease status, with remissions remaining durable at 36 months. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
